首頁 > 市場調查報告書 > 製藥

分子標靶治療學

市場調查報告書

商品編碼

2080138

全球臨床創新、市場發展趨勢、治療標靶化方法及與TRPV6標靶療法相關的臨床試驗趨勢（2026年）

Global TRPV6 Targeted Therapy Clinical Innovation, Market Development Trends, Therapeutic Targeting Modalities & Clinical Trials Insight 2026

出版日期: 2026年07月01日 | 出版商:

KuicK Research | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

「TRPV6標靶療法的全球臨床創新、市場發展趨勢、治療標靶化方法和臨床試驗趨勢（2026）」報告的研究結果和要點

臨床創新與發展趨勢洞察
首批標靶治療預計將於 2032 年商業化。
最先進的臨床研發階段：II/III期
臨床試驗中針對 TRPV6的標靶治療的最新進展：超過 5 種治療方案
按公司、國家、適應症和臨床試驗階段分類的 TRPV6標靶治療的臨床試驗見解。
TRPV6標靶治療在多種癌症中的治療作用
主要藥物試驗開始和完成年份的時間表
競爭格局

TRPV6標靶治療的必要性及本報告的意義

針對TRPV6的治療藥物市場正在離子通道療法和精準醫療領域逐漸形成一個獨特的市場。 TRPV6是一種高選擇性鈣離子通道，參與鈣離子轉運、上皮完整性維持、鈣訊號路徑調控。研究發現，TRPV6功能失調與癌症、發炎、鈣吸收不良、骨骼疾病和腎結石等多種疾病有關，這使得TRPV6成為一個極具潛力的藥物標靶，並為非癌症疾病的治療提供了新的契機。

儘管目前尚無已通過核准的標靶TRPV6的療法，但該領域已從早期檢驗到臨床試驗取得了顯著進展。根據標靶疾病的不同，目前正在研究多種抑製或活化TRPV6的方法，包括小分子化合物、單株抗體、胜肽類藥物和藥物重定位。隨著一些關鍵化合物在中國進入II/III期臨床試驗，TRPV6在早期研發階段展現出巨大的市場潛力。

本報告從生物學和研發管線兩個角度對全球TRPV6標靶療法市場進行了全面評估，目標受群眾外包括製藥公司、生物技術公司、投資者和策略合作夥伴。鑑於人們對標靶各種離子通道療法的興趣日益濃厚，本報告重點介紹了該領域過去的進展和未來的市場前景。

本報告中包含對臨床試驗的深入分析

目前，TRPV6標靶療法的臨床開發主要集中在腫瘤領域，在以該通道過度表達為特徵的腫瘤性疾病（尤其是前列腺癌和卵巢癌）中觀察到了抑製作用。然而，不斷累積的臨床前和轉化數據正日益引起人們對非腫瘤性疾病的興趣，例如發炎性疾病、低血鈣、骨骼疾病，甚至透過選擇性調節或恢復TRPV6活性來預防腎結石形成。

本報告涵蓋了從臨床前階段到I期、I/II期和II/III期的整個臨床研發管線。報告重點在於疾病特異性調控，例如在腫瘤學領域探索拮抗劑，以及在鈣轉運異常和上皮功能障礙相關疾病中考慮促效劑和表達增強策略。此外，報告還評估了基於生物標記的患者選擇策略、結構藥理學和標靶化治療等領域的發展趨勢，這些趨勢將影響未來的臨床研發。

引領 TRPV6 研究與開發的領導企業

目前，TRPV6領域的研究主要由少數生技公司主導，此外，學術機構與離子通道領域的公司之間也存在夥伴關係。例如，Coherent Biopharma、Mabqi、Soricimed Biopharma和UniQuest等公司正致力於開發針對TRPV6的多種治療技術，包括胜肽、抗體、小分子藥物和平台技術。

同時，關於TRPV6結構生物學知識的積累，激發了製藥業對合理藥物設計的興趣；冷凍電鏡和建模技術的進步，將有助於發現新的作用位點，並開發出更最佳化的調變器。生技公司、學術機構和藥物研發公司之間的策略合作，預計將在拓展產品線和轉化研究中發揮關鍵作用。

TRPV6標靶療法的未來前景

針對TRPV6的療法有望在腫瘤治療領域之外得到更廣泛的應用。對TRPV6生物學特性的持續深入研究，凸顯了在以該通道過度激活或鈣離子內流過多為特徵的疾病狀態下選擇性抑制TRPV6的潛力，以及在低鈣血症和上皮屏障功能障礙相關疾病中激活TRPV6的潛在作用。結構藥理學、選擇性配體開發和精準醫學的進一步發展，將有助於快速發現新的TRPV6調變器。

透過後期臨床試驗獲得的更多臨床資訊將有助於明確基於TRPV6的療法的商業性前景。未來的成功取決於臨床檢驗、利用生物標記進行患者篩選以及拓展至多種適應症。本報告涵蓋科學背景、疾病特異性潛力分析、研發管線資訊、與競品對比以及市場評估，是離子通道藥物研發領域最具前景的研究方向之一的寶貴資訊來源。

配體介導的TRPV6活性調控
- TRPV6拮抗作用－機轉與治療證據
- TRPV6激動劑－機轉與治療證據
TRPV6的治療標靶化方式
- 小分子調變器
- 基於抗體的治療標靶化
- 基於胜肽的治療方法
- 藥物再利用策略
TRPV6的結構藥理學和結構為基礎的藥物設計
- TRPV6中的孔道標靶與變構結合位點
- TRPV6的脂質結合、通道門控與變構調節

第5章：癌症中TRPV6的標靶治療

攝護腺癌
乳癌
胰臟癌
卵巢癌
食道癌

第6章：TRPV6標靶治療在非癌症疾病的應用

發炎
鈣吸收不良
骨骼疾病
腎結石

第7章：TRPV6標靶治療相關臨床試驗概述

愛別
國家
公司
適應症
優先事項

第8章：TRPV6標靶治療臨床試驗的全球概況（按公司、國家、適應症和階段分類）

臨床前
第一階段
第一/二期
第二/三期

第9章：全球TRPV6標靶治療市場展望

當前市場趨勢
未來市場機遇

第10章：全球TRPV6標靶治療市場動態

促進者和機會
挑戰與解決方案

第11章競爭格局

Coherent Biopharma
Mabqi
Soricimed Biopharma
UniQuest

簡介目錄圖表

"Global TRPV6 Targeted Therapy Clinical Innovation, Market Development Trends, Therapeutic Targeting Modalities & Clinical Trials Insight 2026" Report Findings & Highlights:

Clinical Innovation & Development Trends Insight
First TRPV6 Targeted Therapy Commercial Availability Expected By 2032
Highest Clinical Phase Of Development: Phase II/III
Insight On TRPV6 Targeted Therapies In Clinical Trials: > 5 Therapies
TRPV6 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
Therapeutic Role of TRPV6 Targeting In Various Cancer Types
Key Drugs Initiation & Completion Year Timeline
Competitive Landscape

Need For TRPV6 Targeted Therapies & Why This Report?

The market for TRPV6 targeted therapies is beginning to become a distinct market within ion channel therapeutics and precision medicine. TRPV6 is a very selective calcium channel that is involved in regulating calcium transport, the integrity of the epithelium, and calcium signaling pathways. TRPV6 dysregulation has been found to be associated with cancer, inflammation, conditions involving calcium malabsorption, bone related conditions, and nephrolithiasis, among others, which makes TRPV6 an interesting drug target and an opportunity for treatment beyond just cancer.

Even though there are no approved treatments targeting TRPV6 so far, the field has progressed a lot since the initial validation stages to clinical testing stage. Various approaches are being studied for inhibition or activation of TRPV6, depending on the disease in question, using small molecules, monoclonal antibodies, peptides, and drug repositioning. With the leading compound having entered Phase II/III clinical trials in China, TRPV6 is a promising drug market at an early stage of development.

This report gives an overall evaluation of the global market for TRPV6 targeted therapies from a biological and pipeline perspective for pharmaceutical companies, biotech firms, investors, and strategic partners. In the light of increased interest in therapies targeting the various ion channel, the report highlights the existing progress and future market prospects in this sector.

Clinical Trial Insights Included In The Report

The clinical development of TRPV6 targeted therapies is at present mainly oriented towards oncology, with inhibitory effects seen in oncological disorders in which there is overexpression of this channel, especially prostate cancer and ovarian cancer. Nevertheless, accumulating preclinical and translational data is increasing interest in non-oncological disorders, including inflammatory diseases, hypocalcemia, bone disorders, and preventing the formation of kidney stones by means of selective modulation or rescue of TRPV6 activity.

The report covers the complete clinical pipeline right from the preclinical stage up to Phase I, Phase I/II, and Phase II/III stages. Special attention is paid to disease specific modulation where antagonists have been explored for oncology applications while agonists and expression enhancement strategies have been explored for disorders related to faulty calcium transport and epithelial dysfunction. The report also provides an assessment of developing trends with respect to biomarker based patient selection strategies, structural pharmacology, and targeting approaches that will impact the future of clinical development.

Major Companies Driving TRPV6 Research & Development

The landscape of TRPV6 space is presently dominated by a few biotech companies along with academic-commercial partnerships in the field of ion channels. Companies such as Coherent Biopharma, Mabqi, Soricimed Biopharma, and UniQuest are working towards the development of various technologies directed against TRPV6 in various therapeutic modalities including peptides, antibodies, small molecules, and platform technologies.

At the same time, growing structural biology insights into TRPV6 have stimulated the pharmaceutical industry's interest in rational drug design, and technological advancements in cryoelectron microscopy and modeling will facilitate the discovery of novel sites of action and optimized modulators. Strategic partnerships among biotechnology firms, academia, and drug discovery enterprises are anticipated to be key contributors to pipeline growth and translational research.

Future Outlook For TRPV6 Targeted Therapies

TRPV6 targeted therapies are anticipated to advance far beyond their current use in oncology. Growing scientific insights into TRPV6 biology have underscored the possibility of selective TRPV6 inhibition in disease states characterized by hyperactivation of the channel and excessive influx of calcium ions and activation in diseases linked to hypocalcemia or barrier function impairment of the epithelium. Further advancements in structural pharmacology, selective ligands development, and precision medicine will likely contribute to rapid discovery of new TRPV6 modulators.

As further clinical information is obtained during late phase trials, the commercial prospects of TRPV6 based therapeutics are likely to be clarified. Further success will depend upon clinical validation, use of biomarkers for patient selection, and diversification across various indications. With the help of the scientific background, insights on disease specific potential, pipeline knowledge, competitive comparison, and market assessment, this report serves as a valuable source of information about one of the promising areas of drug development via ion channels.

1. Research Methodology

2. Transient Receptor Potential (TRP) Channels & TRPV Family Overview

2.1 Overview Of The Transient Receptor Potential (TRP) Channel Family
2.2 Overview Of The TRPV (Vanilloid) Channel Subfamily
2.3 Introduction To TRPV6: Biology, Physiological Functions & Clinical Significance

3. TRPV6 Biology, Function & Pathophysiology

3.1 Structural Architecture & Calcium Selectivity Of TRPV6
3.2 Tissue Distribution, Expression Profile & Cellular Localization Of TRPV6
3.3 Physiological Roles Of TRPV6 In Calcium Homeostasis & Organ Function
3.4 TRPV6 Mediated Calcium Signalling In Health & Disease

4. Pharmacological Modulation & Therapeutic Targeting Of TRPV6

4.1 Ligand Mediated Modulation Of TRPV6 Activity
- 4.1.1 TRPV6 Antagonism - Mechanisms & Therapeutic Rationale
- 4.1.2 TRPV6 Agonism - Mechanisms & Therapeutic Rationale
4.2 Therapeutic Targeting Modalities For TRPV6
- 4.2.1 Small Molecule Modulators
- 4.2.2 Antibody Based Therapeutic Targeting
- 4.2.3 Peptide Based Therapeutic Approaches
- 4.2.4 Drug Repurposing Strategies
4.3 Structural Pharmacology & Structure Based Drug Design Of TRPV6
- 4.3.1 Pore Targeting & Allosteric Binding Sites In TRPV6
- 4.3.2 Lipid Binding, Channel Gating & Allosteric Regulation Of TRPV6

5. TRPV6 Targeted Therapies In Cancer

5.1 Prostate Cancer
5.2 Breast Cancer
5.3 Pancreatic Cancer
5.4 Ovarian Cancer
5.5 Esophageal Cancer

6. TRPV6 Targeted Therapies In Non Cancer Disorders

6.1 Inflammation
6.2 Calcium Malabsorption Disorders
6.3 Bone Diseases
6.4 Kidney Stones

7. Global TRPV6 Targeted Therapies Clinical Trials Overview

7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status

8. Global TRPV6 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase II/III

9. Global TRPV6 Targeted Therapy Market Scenario

9.1 Current Market Trends
9.2 Future Market Opportunities

10. Global TRPV6 Targeted Therapy Market Dynamics

10.1 Drivers & Opportunities
10.2 Challenges & Solutions

11. Competitive Landscape

11.1 Coherent Biopharma
11.2 Mabqi
11.3 Soricimed Biopharma
11.4 UniQuest

簡介目錄圖表

List of Figures

Figure 2-1: TRP Channel Family Overview
Figure 2-2: General Structure Of TRP Channels
Figure 2-3: Classification Of Mammalian TRP Channels
Figure 2-4: TRP Channels Activation Mechanisms
Figure 2-5: Functional Classification Of TRPV Subfamily
Figure 2-6: Functional Diversity Of TRPV1-TRPV6
Figure 2-7: Historical Timeline of TRPV6 Research
Figure 2-8: Physiological Roles of TRPV6 in Different Organs
Figure 2-9: Regulation Of TRPV6 Expression
Figure 2-10: Consequences of TRPV6 Dysfunction
Figure 2-11: From Calcium Transporter To Cancer Target
Figure 2-12: Why TRPV6 IS An Attractive Drug Target
Figure 3-1: Structural Basis Of TRPV6 Function
Figure 3-2: Regulation Of TRPV6 By Lipids & Calmodulin
Figure 3-3: Structural Basis Of Pharmacological Inhibition By 2-APB
Figure 3-4: Organ Distribution Of TRPV6 Expression
Figure 3-5: Physiological Functions of TRPV6
Figure 3-6: TRPV6 In Intestinal Calcium Absorption
Figure 3-7: Role Of TRPV6 In Placental Calcium Transport
Figure 3-8: TRPV6 In Male Reproductive Physiology
Figure 3-9: TRPV6 In Bone Homeostasis
Figure 3-10: TRPV6 In Epidermal Differentiation
Figure 3-11: Consequences of TRPV6 Loss- & Gain-of-Function
Figure 4-1: Overview Of TRPV6 Modulation
Figure 4-2: Core Principle Of TRPV6 Antagonism
Figure 4-3: TRPV6-Calcium-NFAT Oncogenic Axis & Its Inhibition
Figure 4-4: Antagonism Effects On Cancer Cell Fate
Figure 4-5: Core Principle Of TRPV6 Agonism
Figure 4-6: Vitamin D-TRPV6 Regulatory Axis & Agonism Concept
Figure 4-7: Safety Window Concept In TRPV6 Agonism
Figure 4-8: Small Molecule TRPV6 Inhibition Strategy
Figure 4-9: Binding Sites Of TRPV6 Small Molecule Inhibitors
Figure 4-10: Mechanism Of TRPV6-Targeting Antibody MQI-201
Figure 4-11: Mechanism Of Antitumor Action Of TRPV6-Targeting Peptides
Figure 4-12: Therapeutic Applications Of TRPV6-Targeting Peptides
Figure 4-13: Concept Of Drug Repurposing For TRPV6 Targeted Cancer Therapy
Figure 4-14: Allosteric Inhibition Of TRPV6 By Econazole
Figure 4-15: Pore blockade vs Allosteric inhibition - Mechanism
Figure 4-16: PIP2-Dependent Gating Mechanism
Figure 4-17: Lipid Occupancy Vs Drug Displacement Mechanism
Figure 5-1: Crosstalk With Androgen Signaling + SOCE
Figure 5-2: Hormonal Regulation & Drug Modulation Of TRPV6
Figure 5-3: CBP-1008-01 Phase 1 (NCT04740398) Study - Initiation & Completion Year
Figure 5-4: TRPV6 & Chemoresistance
Figure 6-1: Context-Dependent Role Of TRPV6 In Inflammatory Diseases
Figure 6-2: Inflammatory Disease - Therapeutic Strategy Based On TRPV6 Activity
Figure 6-3: Physiological Role Of TRPV6 In Systemic Calcium Homeostasis
Figure 6-4: Calcium Malabsorption Disorders - Therapeutic Strategies Targeting TRPV6
Figure 6-5: Consequences Of TRPV6 Deficiency In Calcium Malabsorption (Secondary Hyperparathyroidism)
Figure 6-6: Central Role Of TRPV6 In Bone Homeostasis
Figure 6-7: Therapeutic Strategies Targeting TRPV6 in Bone Diseases
Figure 6-8: TRPV6 In Calcium Homeostasis & Kidney Stone Formation
Figure 6-9: Mechanisms Of Hypercalciuria Associated With TRPV6
Figure 6-10: Genetic Variants Of TRPV6 & Risk Of Nephrolithiasis
Figure 6-11: Current vs Future Management Of Nephrolithiasis
Figure 7-1: Global - Number Of TRPV6 Inhibitors In Clinical Trials By Phase, 2026
Figure 7-2: Global - Number Of TRPV6 Inhibitors In Clinical Trials By Country, 2026
Figure 7-3: Global - Number Of TRPV6 Inhibitors In Clinical Trials By Company , 2026
Figure 7-4: Global - Number Of TRPV6 Inhibitors In Clinical Trials By Indication, 2026
Figure 7-5: Global - Number Of TRPV6 Inhibitors In Clinical Trials By Priority Status , 2026
Figure 9-1: Global TRPV6 Targeting Therapy - Future Market Opportunities
Figure 10-1: Global TRPV6 Targeting Therapy - Drivers & Opportunities
Figure 10-2: Global TRPV6 Targeting Therapy - Challenges & strategic Solutions